Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Retrieved on:
Tuesday, January 16, 2024
MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
Key Points:
- Three main pillars to unlock the potential of proprietary technology platforms and intellectual property:
MONT-SAINT-GUIBERT, Belgium, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024. - Michel Lussier, interim Chief Executive Officer of Celyad Oncology, commented: “2023 has been a very important year for Celyad Oncology, after the changes that occurred in 2022.
- We have shared new data at several scientific and business conferences along the year, and published in high impact peer-reviewed journals.
- Celyad Oncology will attend the 7th CAR-TCR Europe summit in London, UK (February 27-29, 2024), the must-attend forum to brainstorm and stay at the forefront of cell therapy innovations.